Meeting
2022 ASCO Annual Meeting
Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).
Authors
Philippe L. Bedard
University of Toronto, Toronto, ON, Canada
Philippe L. Bedard , Melissa Kate Accordino , Andres Cervantes , Valentina Gambardella , Erika P. Hamilton , Antoine Italiano , Dejan Juric , Kevin Kalinsky , Ian E. Krop , Mafalda Oliveira , Cristina Saura , Peter Schmid , Nicholas C. Turner , Andreea Varga , Noopur Shankar , Jennifer Schutzman , Stephanie Royer-Joo , Miguel Valero Martin , Komal L. Jhaveri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT03006172
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1052)
DOI
10.1200/JCO.2022.40.16_suppl.1052
Abstract #
1052
Poster Bd #
430
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
First Author: Joohyuk Sohn
Poster
2023 ASCO Annual Meeting
A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).
First Author: Candace Bavette Mainor
Poster
2020 ASCO Virtual Scientific Program
Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC).
First Author: Robert Wesolowski
Poster
2018 ASCO Annual Meeting
Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009).
First Author: Andres Forero-Torres